Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

NCT06868576
completedphase_4

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

NCT03677336
unknownphase_2

Progesterone to Prevent Preterm Delivery

NCT03428685
unknownphase_4

Progesterone and Doppler in Recurrent Abortion

NCT03267771

Clinical Trials (4)

Showing 4 of 4 trials
NCT06868576Phase 3

PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

Completed
NCT03677336Phase 4

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

Completed
NCT03428685Phase 2

Progesterone to Prevent Preterm Delivery

Unknown
NCT03267771Phase 4

Progesterone and Doppler in Recurrent Abortion

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4